December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Anirban Maitra: Revolution Medicines has launched its phase 3 study of RMC-6236
Oct 22, 2024, 15:58

Anirban Maitra: Revolution Medicines has launched its phase 3 study of RMC-6236

Anirban Maitra, Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center, shared a post on X:

Revolution Medicines has launched its ph 3 study of RMC-6236 (RASolute 302) in patients with previously treated Pancreatic Cancer.

1:1 randomization against physician’s choice of chemotherapy.

A registration trial for KRAS inhibitor in pancreatic cancer!”

anirban maitra

Additional information

 

Dr. Anirban Maitra serves as Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center since August 2013, and directs the Sheikh Ahmed Pancreatic Cancer Research Center. He leads an NCI-funded laboratory dedicated to pancreatic cancer research, focusing on genetics and molecular pathology in human and mouse models. His research aims to advance early detection and interception strategies to enhance patient survival rates in pancreatic cancer.